This study involves testing a new treatment for moderate-to-severe asthma. Asthma is a condition where your airways narrow, making it hard to breathe. In this study, mesenchymal stem cells (MSCs), which are special cells that can help reduce inflammation and repair body tissues, are being tested. Some MSCs are primed with something called interferon gamma, which may enhance their effects. The study will look at whether these MSCs are safe and how much can be given safely to young adults with asthma.
Key Points:
- Duration: The study lasts about 1 year with up to 12 visits.
- Participants: Young adults aged 18-30 with moderate-to-severe asthma.
- Compensation: Participants will be compensated for their time and travel.
Participants will receive one infusion of MSCs at one of two dose levels. The research will take place at Children's Healthcare of Atlanta and Emory University. Potential benefits include closely monitored respiratory health and contributing to future asthma treatments. However, there may not be direct benefits for everyone. Eligibility requires having asthma since childhood and being between 18 and 30 years old. Participants cannot smoke or have other serious health issues. They should not be involved in other drug trials during the study.